Synthesis and studies on antidepressant and anticonvulsant activities of some 3-(2-furyl)-pyrazoline derivatives

European Journal of Medicinal Chemistry

Volumn 42, Issue 3, 2007, Pages 373-379

  Özdemir, Zuhal ^a   Kandilci, H Burak ^a   Gümüşel, Bülent ^a   Çaliş, Ünsal ^a   Bilgin, A Altan ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Anticonvulsant activity; Antidepressant activity; Pyrazolines; Thiocarbamoyl compounds

Indexed keywords

1 N ALLYLTHIOCARBAMOYL 3 (2 FURYL) 5 PHENYL 2 PYRAZOLINE; 1 N ALLYLTHIOCARBAMOYL 3,5 DI(2 FURYL) 2 PYRAZOLINE; 1 N ETHYLTHIOCARBAMOYL 3 (2 FURYL) 5 PHENYL 2 PYRAZOLINE; 1 N ETHYLTHIOCARBAMOYL 3,5 DI(2 FURYL) 2 PYRAZOLINE; 1 N METHYLTHIOCARBAMOYL 3 (2 FURYL) 5 PHENYL 2 PYRAZOLINE; 1 N METHYLTHIOCARBAMOYL 3,5 DI(2 FURYL) 2 PYRAZOLINE; 1 N PHENYLTHIOCARBAMOYL 3 (2 FURYL) 5 PHENYL 2 PYRAZOLINE; 1 N PHENYLTHIOCARBAMOYL 3,5 DI(2 FURYL) 2 PYRAZOLINE; 1 THIOCARBAMOYL 3 (2 FURYL) 5 PHENYL 2 PYRAZOLINE; 1 THIOCARBAMOYL 3,5 DI(2 FURYL) 2 PYRAZOLINE; 1,5 DIPHENYL 3 (2 FURYL) 2 PYRAZOLINE; 1,5 DIPHENYL 3 (2 FURYL)PYRAZOLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; PENTETRAZOLE; PYRAZOLINE DERIVATIVE; TRANYLCYPROMINE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SYNTHESIS; ELECTRIC SHOCK; FORCED SWIMMING TEST; INFRARED SPECTROSCOPY; MALE; MASS SPECTROMETRY; MICROANALYSIS; MOUSE; NEUROTOXICITY; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; SEIZURE; TOXICITY TESTING;

ANIMALS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; CONVULSANTS; ELECTROSHOCK; FURANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MUSCULOSKELETAL EQUILIBRIUM; NEUROTOXICITY SYNDROMES; PENTYLENETETRAZOLE; PYRAZOLES; SEIZURES; SPECTROPHOTOMETRY, ULTRAVIOLET; STRUCTURE-ACTIVITY RELATIONSHIP; SWIMMING;

EID: 33847411932     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2006.09.006     Document Type: Article

References (20)

1. Parmar S.S., Pandey B.R., Dwivedi C., and Harbison R.D. J. Pharm. Sci. 63 (1974) 1152-1155
2. Soni N., Pande K., Kalsi R., Gupta T.K., Parmar S.S., and Barthwal J.P. Res. Commun. Chem. Pathol. Pharmacol. 56 (1987) 129-132
3. Chimenti F., Maccioni E., Secci D., Bolasco A., Chimenti P., Granese A., Befani O., Turini P., Alcaro S., Ortuso F., Cirilli R., La Torre F., Cardia M.C., and Distinto S. J. Med. Chem. 48 (2005) 7113-7122
4. Bilgin A.A., Palaska E., Sunal R., and Gümüşel B. Pharmazie 49 (1994) 67-69
5. Bilgin A.A., Palaska E., and Sunal R. Arzneimittel-forschung/Drug Res. 43 (1993) 1041-1044
6. Bilgin A.A., Yeşilada A., Palaska E., and Sunal R. Arzneimittel-forschung/Drug Res. 42 (1992) 1271-1273
7. Gökhan N., Yeşilada A., Uçar G., Erol K., and Bilgin A.A. Arch. Pharm. Med. Chem. 336 (2003) 362-371
8. Ruhoǧlu O., Özdemir Z., Çali{dotless}ş U., Gümüşel B., and Bilgin A.A. Arzneimittel-forschung/Drug Res. 55 (2005) 431-436
9. P. İyidoǧan, Z. Özdemir, B. Kandilci, B. Gümüşel, Ü. Çali{dotless}ş, A.A. Bilgin, J. Fac. Pharm. İstanbul, in press.
10. Porsolt R.D., Bertin A., and Jalfre M. Arch. Int. Pharmacodyn. Ther. 229 (1977) 327-336
11. Schäfer H. Handbook of Experimental Pharmacology: Antiepileptic Drugs. In: Frey H.H., and Janz D. (Eds) (1985), Springer-Verlag, Berlin 199-210
12. Krall R.L., Penry J.K., White B.G., Kupferberg H.J., and Swinyard E.A. Epilepsia 19 (1978) 409-428
13. Ried W., and Dankert G. Chem. Ber. 90 (1957) 2707-2711
14. Angeloni A.S., Bellotti A., and Coghi E. Ann. Chim. 53 (1963) 1392-1398
15. Porsolt R.D. Antidepressants: Neurochemical, Behavioural and Clinical Perspectives. In: Enna S.J., Malick J.B., and Richelson E. (Eds) (1981), Raven Press, New York 129-139
16. Willner P., and Mitchell P.J. Behav. Pharmacol. 13 (2002) 169-188
17. Kostanecki St.v., and Podrajansky L. Chem. Ber. 29 (1896) 2248-2250
18. Kaufmann W.E., and Adams R. J. Am. Chem. Soc. 45 (1923) 3029-3044
19. Weygand C., and Strobelt F. Chem. Ber. 68B (1935) 1839-1847
20. Emerson W.S., and Patrick T.M. J. Org. Chem. 14 (1949) 790-797